Health Technology · Pharmaceuticals: Major · NSE: INFINIUM · data 2026-10-09
Infinium Pharmachem Ltd.
Health check: Strong (7.4/10 on quality, valuation vs sector, growth and momentum).
Open full analysis — chart, results, balance sheet, red flags →Key figures
Price
₹312.5
Market cap
₹488 cr
P/E
40.1
P/B
4
ROE
10.5%
ROCE
13.5%
Debt / equity
0.19
Dividend yield
0.00%
1-year return
27.6%
52-week high
₹324.5
52-week low
₹189.4
Operating margin
9.8%
Growth
| Revenue (last 12 months) | ₹190 cr |
| Net profit (last 12 months) | ₹12 cr |
| Sales growth, 3 years (yearly) | 18.4% |
| Profit growth, 3 years (yearly) | 8.6% |
Similar companies
Valiant Laboratories Ltd. (VALIANTLAB) · Praveg Limited (PRAVEG) · Albert David Ltd (ALBERTDAVD) · Medicamen Biotech Limited (MEDICAMEQ) · Jenburkt Pharmaceuticals Ltd (JENBURPH)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open INFINIUM in NSE Scanner →